- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01489553
Egg Oral Immunotherapy
Study Overview
Status
Conditions
Detailed Description
The primary objective is to study the efficacy of baked egg oral immunotherapy. The secondary objectives are to determine the safety of allergen-specific immunotherapy for egg allergy through ingestion of baked egg products and whether it will ultimately lead to a desensitized state for native egg. We will also examine if quality of life is improved by expansion of diets.
Subjects aged six to 17 years with a history of egg protein allergy will be recruited from The Children's Hospital of Philadelphia (CHOP) Allergy practice (main campus and satellite locations).
Prior to and after the desensitization to baked egg, we will conduct double blind placebo-controlled food challenges to native egg protein. During the desensitization phase, we will give increasing doses of baked egg (meringue cookie or equivalent) on a weekly basis, as tolerated.
The primary endpoint of the study includes the percentage of subjects who can successfully complete the food challenge to native egg once they have completed the desensitization protocol to baked egg. Secondary outcome measures include egg-specific IgE, quality of life before and after desensitization, and egg skin prick test size.
Study Type
Enrollment (Actual)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
Subjects must satisfy all inclusion criteria:
- Subjects must be age six to 17 years and have a history of egg allergy. Subjects shall maintain strict avoidance of consumption of all egg protein containing foods.
Subjects will have a history (within the past six months) of a positive skin prick test to egg extract or an immunocap IgE level greater than 0.35 kU/L, and a positive allergic reaction history to egg within the past 12 months.
a. Subjects will be accepted to the study if they have had a positive food challenge conducted at CHOP in the three months prior to the start of the study.
- Subjects must be in good health, as determined by medical history and physical examination performed by a study physician.
Females of childbearing potential must be using an effective method of contraception, including abstinence, and agree to continue to practice an acceptable method of contraception for the duration of their participation in the study.
If a positive pregnancy test was obtained during the study, the subject will be asked to withdraw from the study.
- Informed consent of parent or legal guardian is required.
Exclusion Criteria:
Subjects will be excluded from the study if they meet any one of the following criteria:
- Ability to tolerate baked goods containing egg or the ability to tolerate a serving size of egg (6.3 grams of egg protein.)
- Pregnancy.
- A history of food protein induced enterocolitis syndrome to egg.
- A history of eosinophilic esophagitis, where egg has been identified as a causative food.
- A history of anaphylaxis requiring overnight hospitalization.
- A history of intubation related to asthma and/or a history of an intensive care unit admission for asthma management.
- A current diagnosis of severe persistent asthma [FEV1 (forced expiratory volume in 1 second) < 60% of predicted, as defined by NHLBI (National Heart, Lung, and Blood Institute) guidelines, despite current therapy].
- A current diagnosis of severe atopic dermatitis.
- A serious chronic medical condition, including neurologic, hepatic, renal, endocrine, cardiovascular, gastrointestinal, pulmonary, or metabolic disease.
Use of oral or injection steroids within one month of protocol initial visit.
a. Should it become necessary for a subject to be on systemic corticosteroids while on the study, the subject will either be withdrawn from the study or the use of corticosteroids during the study will be taken into account during data analysis. The PI and lead investigators will make that decision based on the individual case.
- An acute illness within one week prior to the first dose of oral immunotherapy.
- Use of antihistamines within three days prior to Double blind placebo-controlled food challenge (DBPCFC).
- Use of chronic immunomodulatory therapy.
- Participation in another experimental therapy study.
- Participation in a study for the treatment of food allergy in the past 12 months.
- Inability to discontinue antihistamines for skin testing and food challenges.
- A positive pregnancy test.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of children completing desensitization
Time Frame: Baseline & 12 months
|
Evaluate proportion of subjects who successfully complete the food challenge to native egg upon completion of the desensitization protocol to baked egg.
|
Baseline & 12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Egg specific IgE values at the beginning and end of desensitization
Time Frame: Baseline & 12 months
|
Specific IgE values will be compared for egg at the beginning and the end of the desensitization protocol.
|
Baseline & 12 months
|
Change in quality of life variables
Time Frame: Baseline & 12 months
|
Comparison of quality of life before and after desensitization through the completion of a voluntary and confidential survey.
|
Baseline & 12 months
|
Number of participants with adverse events
Time Frame: Baseline & 12 months
|
Determine the safety of allergen-specific immunotherapy for egg allergy through ingestion of baked egg products and whether it will ultimately lead to a desensitized state for native egg.
|
Baseline & 12 months
|
Collaborators and Investigators
Investigators
- Principal Investigator: Jonathan M. Spergel, MD, PhD, Children's Hospital of Philadelphia
- Study Director: Rushani W. Saltzman, MD, Children's Hospital of Philadelphia
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IRB 11-008294
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Egg Hypersensitivity
-
Ospedale Buon Consiglio FatebenefratelliCompleted- Egg HypersensitivityItaly
-
Aimmune Therapeutics, Inc.TerminatedHen Egg AllergyUnited States
-
University of North Carolina, Chapel HillUniversity of ArkansasCompletedFood HypersensitivityUnited States
-
Turku University HospitalUnknownEgg Allergy | Cow's Milk Allergy
-
Tampere University HospitalOulu University Hospital; University of OuluRecruiting
-
National Institute of Allergy and Infectious Diseases...Immune Tolerance Network (ITN)CompletedEgg Allergy | Hypersensitivity | Eczema | Food AllergyUnited Kingdom
-
Universitair Ziekenhuis BrusselCompletedHypersensitivity | Allergy, Egg | Soy AllergyBelgium
-
Helsinki University Central HospitalCompleted
-
Dominque BullensJessa Hospital; Imelda Hospital, Bonheiden; AZ Sint-Jan AV; Algemeen Ziekenhuis...Active, not recruiting
-
Murdoch Childrens Research InstituteRecruitingFood Allergy | Food Allergy in InfantsAustralia